Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, United States.
Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, United States.
J Pharm Sci. 2022 Dec;111(12):3275-3286. doi: 10.1016/j.xphs.2022.09.005. Epub 2022 Sep 16.
A new type of lamellae-like particles was observed in protein based liquid therapeutic protein drug product (DP) packaged in standard (STD) and delamination controlled (DC) Type IB glass vials stored at 2-8°C as early as two weeks after manufacture. These particles were determined to be remarkably different from lamellae in not only in their chemical composition, but in the mechanism by which these are formed. The lamellae-like particles were an ultra-thin (< 200 nm) film, appeared curled, sheet-like, folded with no defined edges identified as lamellar silica composed of silica and polysorbate 80 (PS 80). It was also observed that the lamellar silica particles, when formed in a given drug product lot, not only were observed in a small percentage of vials, but also remained at low (≤ 5) numbers in affected vials, often decreasing in number over time. This is in contrast to the large number of commonly reported glass lamellae (hundreds per vial) observed in vials prone to delamination with a glass vial interior showing a delaminated inner surface. In this case study, evidence from low Si leachable levels in solution and various surface analytical techniques supported the conclusion that there was neither delamination nor early signs of glass delamination like reaction zones occurring in those impacted vials, regardless. A mechanism for particle formation was hypothesized and experimentally confirmed. Lamellar silica particles are composed of an admixture of condensed silica and PS 80 deposited on the interior walls of glass vials, which form and may be released into solution over time. The root cause was determined to be conditions present during preparation of the vials for drug product filling, specifically the vial washing and depyrogenation steps. These conditions are known to make glass vials prone to delamination; in this case study, they resulted in interactions between the glass and PS 80 present in the formulation. Incomplete drying of the glass vials during depyrogenation in closed ovens was confirmed as the contributing factors that led to lamellar silica particle formation via the studies of silicate spiked into the DC Type IB glass vials filled with the mAb DP in which lamellar silica particles were observed. Prevention of lamellar silica particles formation was successfully achieved through optimization of the duration and pressure of air blow during the vial washing and drying process in a depyrogenation oven. This was evidenced by the lack of appearance of the lamellar silica particles over 48 months for the DP lots filled post optimization. Additionally, the formation of lamellar silica was also mitigated by changing the vial washing process from a closed oven process to a tunnel process, which allowed for improved air flow and hence better drying of the vial primary container.
早在制造后两周,在 2-8°C 下储存的标准(STD)和分层控制(DC)IB 型玻璃小瓶中包装的蛋白质基础液体制剂(DP)中,就观察到了一种新型的薄片样颗粒。这些颗粒在化学组成上与薄片明显不同,形成机制也不同。薄片样颗粒是一种超薄(<200nm)薄膜,呈卷曲、片状、折叠状,没有确定的边缘,被鉴定为由二氧化硅和聚山梨酯 80(PS 80)组成的层状硅。还观察到,当在给定的药物产品批次中形成层状硅颗粒时,不仅在小瓶中的比例较低(<5%),而且在受影响的小瓶中数量也较低,随着时间的推移,数量通常会减少。这与大量常见的报告的玻璃薄片(每个小瓶数百个)形成鲜明对比,这些玻璃薄片易于分层,并且玻璃小瓶的内部表面显示出分层的内表面。在本案例研究中,来自溶液中低 Si 可浸出水平和各种表面分析技术的证据支持了这样的结论,即在受影响的小瓶中既没有分层,也没有发生玻璃分层等反应区域的早期迹象。提出了一种颗粒形成的机制,并通过实验得到了证实。层状硅颗粒由冷凝硅和 PS 80 的混合物组成,沉积在玻璃小瓶的内壁上,随着时间的推移形成并可能释放到溶液中。根本原因被确定为在为药物产品填充准备小瓶时存在的条件,特别是小瓶的清洗和除热源步骤。这些条件已知会使玻璃小瓶易于分层;在本案例研究中,它们导致了玻璃与制剂中存在的 PS 80 之间的相互作用。在封闭的烤箱中进行除热源时,不完全干燥玻璃小瓶被确认为导致通过向填充有 mAb DP 的 DC IB 型玻璃小瓶中加入硅酸盐来观察到层状硅颗粒形成的因素。通过优化在除热源烤箱中进行小瓶清洗和干燥过程中的空气吹制时间和压力,成功地防止了层状硅颗粒的形成。这从优化后填充的 DP 批次中超过 48 个月没有出现层状硅颗粒这一事实中得到了证明。此外,通过将小瓶清洗工艺从封闭的烤箱工艺改为隧道工艺,也减轻了层状硅的形成,这允许更好的空气流动,从而更好地干燥小瓶的主容器。